Therapeutic resistance to anti-oestrogen therapy in breast cancer

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• Oestrogen receptor-α (ER) signaling is central to mammary gland development and breast cancer.
• ER antagonism is a successful therapy but faces resistance.
• Breast cancer evolution under therapy pressure is a significant clinical challenge.

Purpose of the Study:

• To elucidate the molecular mechanisms driving breast cancer evolution under anti-oestrogen therapy.
• To understand the prevalence and impact of ESR1 mutations in metastatic breast cancer.
• To inform the development of novel therapeutic strategies for treatment-refractory ER+ breast cancer.

Main Methods:

• Analysis of ESR1 gene mutations in primary versus metastatic breast cancer samples.
• Investigation of ER signaling pathways in the context of anti-oestrogen resistance.
• Evaluation of the clinical efficacy of next-generation ER antagonists.

Main Results:

• ESR1 mutations, leading to oestrogen-independent ER activity, are rare in primary tumors but prevalent (20-40%) in metastatic disease after anti-oestrogen treatment.
• These mutations signify the 'evolvability' of ER-positive breast cancer under therapeutic pressure.
• Next-generation ER antagonists targeting ESR1 mutations have been developed and approved, demonstrating clinical importance.

Conclusions:

• ER-positive breast cancer exhibits significant evolvability, particularly through ESR1 mutations, leading to therapeutic resistance.
• Understanding these evolutionary processes is critical for overcoming treatment failure.
• Targeted therapies against ESR1 mutations represent a new paradigm for managing advanced ER+ breast cancer.